-- 提供人工智能劳动力准备平台的Docebo(DCBO.TO)周二在美国盘前交易中上涨1%,此前该公司公布了截至2026年3月31日的第一季度未经审计的初步财务业绩,并上调了截至2026年12月31日的财年业绩预期。 在未经审计的第一季度初步财务业绩中,该公司表示,预计总收入将在6540万美元至6560万美元之间,较2025年第一季度的5730万美元增长14.3%。FactSet汇总的第一季度销售额普遍预期为6350万美元。 该公司还表示,截至2026年3月31日止三个月的调整后EBITDA预计在1080万美元至1100万美元之间,较2025年第一季度的890万美元增长22.5%。 该公司进一步指出,截至2026年3月31日,年度经常性收入(ARR)预计为2.489亿美元,较2025年3月31日的2.251亿美元增长10.6%。该公司补充道:“由于汇率波动的影响,本季度ARR减少了140万美元。” Docebo 还修订了截至 2026 年 12 月 31 日的财年业绩预期。该公司目前预计 2026 财年总收入将在 2.71 亿美元至 2.73 亿美元之间,高于此前预期的 2.675 亿美元至 2.695 亿美元。FactSet 汇总的该财年销售额一致预期为 2.681 亿美元。 该公司还将截至 2026 年 12 月 31 日的财年调整后 EBITDA 预期范围从此前预期的 5250 万美元至 5450 万美元上调至 5450 万美元至 5650 万美元。 对于截至 2026 年 12 月 31 日的财年,该公司目前预计订阅收入将在 2.535 亿美元至 2.555 亿美元之间,高于此前预期的 2.515 亿美元至 2.535 亿美元。 “Docebo在2026年开局表现卓越,各项业绩均超出预期,进一步巩固了我们在市场上的领先地位。我们的出色表现既体现了公司严谨的执行力,也反映了市场对我们人工智能劳动力准备平台日益增长的需求,因为在日益复杂的运营环境中,各组织都将劳动力准备放在首位。”总裁兼首席执行官Alessio Artuffo表示,“Docebo Inspire大会今天在迈阿密拉开帷幕,我们期待展示能够进一步巩固我们市场地位的创新成果。” 正如之前宣布的那样,公司预计将于2026年5月8日(星期五)美股开盘前公布2026年第一季度完整财务业绩。 昨日,Docebo股票(股票代码:DCBO)在加拿大上涨了3%。
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%